About Dr. Khan
Arif Khan, MD, is a Board Certified Psychiatrist and Adjunct Professor of Psychiatry at Duke University School of Medicine. He is the Medical Director and Principal Investigator at Northwest Clinical Research Center in Bellevue, Washington. Dr. Khan has been conducting clinical trials in the greater Seattle area since 1984 and founded NWCRC in 1995.
Dr. Khan as conducted over 90 clinical trials studying depression. His research has been instrumental in the FDA approval of medication such as venlafaxine, paroxetine, citalopram, duloxetine and vilazadone, just to name a few. A sample of his published works on depression are linked below.
Vedantam S. Against depression a sugar pill is hard to beat. Washington Post: May 7th, 2002.
Friedman RA. Can the placebo treat depression? That depends. New York Times: June 25th, 2002.
Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? International Journal of Neuropsychopharmacology 5: 193-197, 2002.
Khan A, Kolts RL, Thase ME, Krishnan KR, Brown WA. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. American Journal of Psychiatry, 160(11): 2045-2049, 2004.
Khan A, Warner H, Brown, WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Archives of General Psychiatry 57: 311-317, 2000.